Literature DB >> 18844497

Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients.

Magdalena Groblewska1, Barbara Mroczko, Urszula Wereszczyńska-Siemiatkowska, Bogusław Kedra, Marta Lukaszewicz, Andrzej Baniukiewicz, Maciej Szmitkowski.   

Abstract

BACKGROUND: Colorectal cancer is one of the most common cancers of the gastrointestinal tract and the fourth cause of cancer death in the world. It has been shown that local chronic inflammation may lead to colorectal carcinogenesis via adenomatous polyps. Interleukin-6 and C-reactive protein are biomarkers of inflammation and indicators of the immune response to tumors.
METHODS: Serum levels of interleukin-6, carcinoembryonic antigen and carbohydrate antigen 19-9 were determined using immunoenzymatic assays, and C-reactive protein concentrations by immunoturbidimetric kits in 76 colorectal cancer patients before surgery, in 38 colorectal adenoma patients and in 35 healthy controls.
RESULTS: Serum levels of interleukin-6, C-reactive protein and carcinoembryonic antigen were significantly higher in cancer patients when compared to adenoma patients and healthy subjects, and increased in more advanced stages of disease and in patients with non-resectable tumors. Based on Cox's analysis, the elevated preoperative serum level of C-reactive protein was an independent significant prognostic factor for patients' survival.
CONCLUSIONS: Our findings suggest the usefulness of interleukin-6 in the diagnosis of colorectal cancer patients and C-reactive protein in the survival prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844497     DOI: 10.1515/CCLM.2008.278

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  43 in total

Review 1.  Body mass index and colon cancer screening: the road ahead.

Authors:  Kanwarpreet Tandon; Mohamad Imam; Bahaa Eldeen Senousy Ismail; Fernando Castro
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial.

Authors:  Myfanwy H Hopkins; Joy Owen; Thomas Ahearn; Veronika Fedirko; W Dana Flanders; Dean P Jones; Roberd M Bostick
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-30

3.  Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.

Authors:  Barbara Mroczko; Magdalena Groblewska; Mariusz Gryko; Bogusław Kedra; Maciej Szmitkowski
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

4.  Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.

Authors:  Anna E Coghill; Polly A Newcomb; Peter T Campbell; Andrea N Burnett-Hartman; Scott V Adams; Elizabeth M Poole; John D Potter; Cornelia M Ulrich
Journal:  Gut       Date:  2010-11-04       Impact factor: 23.059

Review 5.  Serum tests for colorectal cancer screening.

Authors:  James Creeden; Frank Junker; Sabine Vogel-Ziebolz; Douglas Rex
Journal:  Mol Diagn Ther       Date:  2011-06-01       Impact factor: 4.074

6.  Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop.

Authors:  Danielle M Carrick; Anil K Chaturvedi; Meredith S Shiels; Rao L Divi; Kelly K Filipski; Elizabeth F Hebert; Mukesh Verma; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-24       Impact factor: 4.254

7.  Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Eiji Noda; Hiroshi Ohtani; Yukio Nishiguchi; Kosei Hirakawa
Journal:  Surg Today       Date:  2014-05-10       Impact factor: 2.549

8.  Relationship between Community Periodontal Index and Fecal Hemoglobin Concentration, an Indicator for Colorectal Neoplasm.

Authors:  A M-F Yen; H Lai; J C-Y Fann; S Y-H Chiu; S L-S Chen
Journal:  J Dent Res       Date:  2014-06-17       Impact factor: 6.116

9.  The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.

Authors:  Barbara Mroczko; Magdalena Groblewska; Bogna Okulczyk; Bogusław Kedra; Maciej Szmitkowski
Journal:  Int J Colorectal Dis       Date:  2010-06-17       Impact factor: 2.571

Review 10.  CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?

Authors:  Brendon J Coventry; Martin L Ashdown; Michael A Quinn; Svetomir N Markovic; Steven L Yatomi-Clarke; Andrew P Robinson
Journal:  J Transl Med       Date:  2009-11-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.